Prime Medicine said the New Zealand regulator Medsafe cleared its clinical trial application for PM-577a in Wilson’s disease. PM-577a is a prime editor investigational therapy, advancing toward human testing after receiving clearance for the study application in the country. Prime editing is a CRISPR-based approach that aims to write genetic changes without making double-strand breaks, and the clearance signals regulatory readiness for clinical-stage evaluation of PM-577a’s Wilson’s disease program. The clearance adds to Prime Medicine’s international development momentum as it prepares to move from preclinical work into structured clinical dosing and monitoring under New Zealand oversight.